Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most common. Overall efficacy was 87.1% (16 with 1 dose and 11 with 2 doses). Of the 40 patients enrolled at 11 centers in the United States between 15 August 2013 and 16 December 2013, 34 received at least 1 dose of RBX2660 and 31 completed 6-month follow-up. A secondary objective was CDI-associated diarrhea resolution at 8 weeks. The primary objective was product-related AEs.
Intensive surveillance for adverse events (AEs) was conducted daily for 7 days following treatment and then at 30 days, 60 days, 3 months, and 6 months. Patients with at least 2 recurrent CDI episodes or at least 2 severe episodes resulting in hospitalization were enrolled in a prospective, multicenter open-label study of RBX2660 administered via enema. Our aim in this study was to assess the safety and effectiveness of RBX2660 (microbiota suspension), a commercially prepared FMT drug manufactured using standardized processes and available in a ready-to-use format.
Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, yet availability of a standardized, safe, and effective product has been lacking. Managing recurrent Clostridium difficile infection (CDI) presents a significant challenge for clinicians and patients.
0 kommentar(er)
